[Report] Sanofi-Aventis PharmaVitae Profile Market Research, Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
  - Externalization strategy
  - Geographic strategy
  - Molecule type strategy
- SWOT analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- M&A history
  - Sanofi-Synthelabo
  - Aventis
  - M&A strategy
    - Increase US market presence
    - Therapy area diversification
    - Patent risk dilution
    - Creation of thrombotic powerhouse
  - Current corporate structure
CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
  - Revenue and growth rate vs. peer setProduct analysis, 2001-06
  - Growth drivers
    - Eloxatine
    - Lantus
    - Plavix
    - Stilnox
    - Lovenox
  - Growth resistors
    - Allegra/Telfast
- Operating revenue and cost analysis, 2001-06
  - Operating revenue/cost analysis
CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
  - Growth drivers
    - Eloxatine
    - Lantus
    - Vaccines franchise
    - Lovenox
    - Eplivanserin
  - Growth resistors
    - Ambien/Stilnox
    - Taxotere
- Therapy area analysis, 2006-12
  - Oncology
  - Endocrine, metabolic & genetic disorders
  - Cardiovascular & hematology
  - Infectious diseases
  - CNS
  - Therapy area focus
- Launches and expiries analysis, 2006-12
  - Launch portfolio
  - Core portfolio
  - Expiry portfolio
  - Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular & hematology
  - Lovenox
    - Overview
    - Sales forecast
    - Newsflow
  - Plavix
    - Overview
    - Sales forecast
    - Newsflow
- Oncology
  - Eloxatine
    - Overview
    - Sales forecast
    - Newsflow
  - Taxotere
    - Overview
    - Sales forecast
    - Newsflow
  - Gardasil
    - Overview
    - Sales forecast
    - Newsflow
- Endocrine, metabolic & genetic disorders
  - Lantus
    - Overview
    - Sales forecast
    - Newsflow
- CNS
  - Ambien/Stilnox
    - Overview
    - Sales forecast
    - Newsflow
  - Eplivanserin
    - Overview
    - Sales forecast
    - Newsflow
- Infectious diseases
  - Menactra
    - Overview
    - Sales forecast
    - Newsflow
- R&D pipeline
CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- Abbreviations
- Exchange rates
- List of Tables
  - Table 1: Peer set overview
  - Table 2: Operating revenue/cost analysis ($m), 2001-06
  - Table 3: Operating cost ratio analysis (% of total revenues), 2001-06
  - Table 4: Product portfolio overview, sales ($m), 2006-12
  - Table 5: Therapy area overview, sales ($m), 2006-12
  - Table 6: Launch portfolio overview, sales ($m), 2006-12
  - Table 7: Core portfolio overview, sales ($m), 2006-12
  - Table 8: Expiry portfolio overview, sales ($m), 2006-12
  - Table 9: Externally developed portfolio ($m), 2006-12
  - Table 10: Molecule type overview, sales ($m), 2006-12
  - Table 11: Key products overview
  - Table 12: Lovenox: overview
  - Table 13: Lovenox: sales forecast ($m), 2006-12
  - Table 14: Lovenox: news flow
  - Table 15: Plavix: overview
  - Table 16: Plavix: sales forecast ($m), 2006-12
  - Table 17: Plavix: news flow
  - Table 18: Eloxatin: overview
  - Table 19: Eloxatin: sales forecast ($m), 2006-12
  - Table 20: Eloxatin: news flow
  - Table 21: Taxotere: overview
  - Table 22: Taxotere: sales forecast ($m), 2006-12
  - Table 23: Taxotere: news flow
  - Table 24: Gardasil: overview
  - Table 25: Gardasil: sales forecast ($m), 2006-12
  - Table 26: Gardasil: news flow
  - Table 27: Lantus: overview
  - Table 28: Lantus: sales forecast ($m), 2006-12
  - Table 29: Lantus: news flow
  - Table 30: Ambien/Stilnox: overview
  - Table 31: Ambien/Stilnox: sales forecast ($m), 2006-12
  - Table 32: Ambien/Stilnox: news flow
  - Table 33: Eplivanserin: overview
  - Table 34: Eplivanserin: sales forecast ($m), 2006-12
  - Table 35: Eplivanserin: news flow
  - Table 36: Menactra: overview
  - Table 37: Menactra: sales forecast ($m), 2006-12
  - Table 38: Menactra: news flow
  - Table 39: Sanofi-Aventis' R&D pipeline (Phase I-registration)
  - Table 40: Exchange rates, 2006
- List of Figures
  - Figure 1: Historical and forecast ethical sales performance (% CAGR), Sanofi-Aventis and Big Pharma peer set
  - Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006
  - Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Sanofi-Aventis
  - Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006
  - Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012
  - Figure 7: SWOT analysis of Sanofi-Aventis
  - Figure 8: Current corporate structure
  - Figure 9: Revenue & growth rate (ethical sales) ($m), 2001-06
  - Figure 10: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06
  - Figure 11: Growth drivers/resistor products of historical revenue performance ($m), 2001-06
  - Figure 12: Operating revenue/cost analysis ($m), 2001-06
  - Figure 13: Operating cost ratio analysis (% of total revenues), 2001-06
  - Figure 14: Ethical revenue ($m) and growth rate (%), 2006-12
  - Figure 15: Top five products by sales ($m), 2006
  - Figure 16: Top five products by sales ($m), 2012
  - Figure 17: Growth drivers and resistors by product, 2006-12
  - Figure 18: Key strategic products, sales ($m), 2006-12
  - Figure 19: Ethical sales by therapy area ($m), 2006-12
  - Figure 20: Growth drivers and resistors by therapy area ($m), 2006-12
  - Figure 21: Ethical sales by therapy area (%), 2006-12
  - Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2006
  - Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2012
  - Figure 24: Launch schedule, sales ($m), 2006-12
  - Figure 25: Core products sales growth ($m), 2006-12
  - Figure 26: Expiry schedule, sales ($m), 2006-12
  - Figure 27: Launch, core and expiry, sales ($m), 2006-12
  - Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Sanofi-Aventis
  - Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 30: Externalization dependency, sales ($m), 2006-12
  - Figure 31: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12
  - Figure 32: Externalization dependency vs. peer set, % total sales, 2006
  - Figure 33: Externalization dependency vs. peer set, % total sales, 2012
  - Figure 34: Geographical sales breakdown ($m), 2006-12
  - Figure 35: Growth drivers and resistors by geography, sales ($m), 2006-12
  - Figure 36: US dependency vs. peer set, % total sales, 2006
  - Figure 37: US dependency vs. peer set, % total sales, 2012
  - Figure 38: Growth drivers and resistors by molecule type, sales ($m), 2006-12
  - Figure 39: Molecule type sales breakdown ($m), 2006-12
  - Figure 40: Biologics dependency vs. peer set, % total sales, 2006
  - Figure 41: Biologics dependency vs. peer set, % total sales, 2012
  - Figure 42: IMS vs. company-reported ethical sales discrepancy ($m), 2006
  - Figure 43: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12

Sanofi-Aventis: PharmaVitae Profile

Table of Contents